-Idecabtagene Vicleucel (Abecma), a BCMA-targeting CAR-T therapy approved in 2021 as the first US FDA-approved CAR-T therapy for MM. It is indicated for patients who have received at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. 276, 277 -Ciltacabtagene Autoleucel (Carvykti), another BCMA-targeting CAR-T therapy approved in 2022, showing deep and durable responses in heavily pre-treated MM patients. 278, 279 -Numerous other BCMA-targeting CAR-T products are under investigation, along with CAR-T therapies targeting alternative antigens. These therapies are being evaluated in clinical trials for their efficacy, safety, and ability to provide long-term remission. • CAR-T | acute myeloid leukemia (AML) CAR-T cell therapy application in AML has been challenging due to several factors: (i) AML lacks a universally expressed, leukemia-specific antigen; (ii) AML is highly heterogeneous, with different patients exhibiting varied expression of potential target antigens; (iii) the bone marrow microenvironment in AML is often immunosuppressive, which can inhibit the function and persistence of CAR-T cells. AML cells and their microenvironment can produce factors that suppress T cell activity or promote T cell exhaustion. Despite these challenges, several antigens have been investigated as potential CAR-T cell targets in AML: